Second Fund 23andMe Complete
Successfully raised 1.1b Yen from institutional investors and corporates.
HiJoJo Partners has successfully completed distribution of its second fund. The unique investment opportunity which closed in December was in the exciting genetics and research platform, 23andMe.
The direct-to-cap table transaction puts HiJoJo Partners and its investors alongside global leaders in VC and PE such as Sequoia and Fidelity as well as big pharma (Glaxo, Johnson & Johnson, etc). HiJoJo and its investors are excited to be part of this opportunity in cutting-edge and transformative technology.